Larger Relationship Between Diabetes and Alzheimer Disease and Related Dementias (ADRD)

Read full text Summarise with VIRAT
Authors: Hiroshi Bando, Hirohisa Urasaki, Masahiro Bando, Akiyo Yoshioka
Cited by: 0
References: 13

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Patients with Alzheimer disease and related dementias (ADRD) tend to develop diabetes more than those without diabetes. Diabetic treatments mainly include DPP4-i, GLP-1RAs, and SGLT2-i. They are reported to decrease neuroinflammation, amyloid beta accumulation, and hyperphosphorylation of tau protein, and to prevent neuronal loss and enhance neurogenesis. Anti-diabetic agents may decrease dementia risk in T2D based on large research data of 4 million individuals. As a result, the odds ratios (OR) for reducing dementia showed SGLT2-i 0.69, GLP-1RA 0.70, DPP4-i 0.86, metformin 0.92, sulfonylurea 1.02, α-GI 1.14, and insulin 1.26. From some studies, GLP-1RAs and SGLT2-i show a similar degree of clinical effect.

Fields of Study & Subjects

Dementia and Cognitive Impairment Research Diabetes Treatment and Management Alzheimer's disease research and treatments

Publication details

Journal / source
Journal of Health Care and Research
Pages
1–1
Publication date
6 March 2026
Language
EN